BioLife Solutions (BLFS) EVP sells shares for tax withholding

Rhea-AI Filing Summary

BioLife Solutions Inc. executive vice president and chief scientific officer Aby J. Mathew reported a small insider sale of company stock. On 12/09/2025, he sold 631 shares of common stock at $25.13 per share. After this transaction, he directly owns 349,755 shares of BioLife Solutions common stock.

The filing states that this sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, which was adopted effective 03-08-2024. The purpose of the plan was to sell shares to cover tax withholding obligations arising from the vesting of restricted stock, indicating this was an automated, tax-related transaction rather than a discretionary open-market sale.

Insider Trade Summary

Net Seller: 631 shares

Net Sell 1 txn

Insider Mathew Aby J.

Role EVP & Chief Scientific Officer

Sold 631 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Common Stock	631	$25.13	$16K

Holdings After Transaction: Common Stock — 349,755 shares (Direct)

Footnotes (1)

1. F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

What insider transaction did BioLife Solutions (BLFS) report in this Form 4?

The report shows that EVP & Chief Scientific Officer Aby J. Mathew sold 631 shares of BioLife Solutions common stock on 12/09/2025 at $25.13 per share.

How many BioLife Solutions (BLFS) shares does the reporting person own after the sale?

Following the reported transaction, Aby J. Mathew beneficially owns 349,755 shares of BioLife Solutions common stock, held in direct ownership.

Was the BLFS insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person, effective 03-08-2024, as disclosed in the explanation of responses.

Why did the BioLife Solutions executive sell 631 shares?

The filing explains that the sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock, rather than as a discretionary sale.

What is the role of the reporting person at BioLife Solutions (BLFS)?

The reporting person, Aby J. Mathew, is identified as an officer of BioLife Solutions, serving as EVP & Chief Scientific Officer.

Is this Form 4 for one reporting person or a group at BioLife Solutions?

The document indicates that it is a Form filed by one reporting person, not a joint or group filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/17/2025 - 05:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mathew Aby J.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		S(1)		631	D	$25.13	349,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Aby J. Mathew	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.